Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 7 clinical trials
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination with nemtabrutinib in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate …

lymphoma
lymphocytic leukemia
chronic lymphocytic leukemia
tyrosine
follicular lymphoma
  • 0 views
  • 28 Oct, 2022
  • 8 locations
DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma

Patients eligible for the study will receive R-DA-EDOCH as the induction therapy and be evaluated by PET CT after the fourth cycle. Patients achieve CR at interim-PET(Deauville score 1-3) will receive either ASCT or the remaining 4 cycles of R-DA-EDOCH, while those achieve PR(Deauville score 4-5) will be rescued by …

etoposide
dexamethasone
b-cell lymphoma
rituximab
doxorubicin
  • 0 views
  • 24 Mar, 2022
  • 1 location
Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Aim of this study will evaluate the efficacy and safety of tislelizumab in combination with lenalidomide in in patients with relapsed or refractory Elderly Patients with non-GCB Diffuse Large B Cell Lymphoma

  • 0 views
  • 25 Mar, 2021
  • 1 location
Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

This study will evaluate the efficacy and safety of camrelizumab in combination with apatinib in in patients with relapsed or refractory diffuse large B cell lymphoma failed from second line chemotherapy.

colony stimulating factor
b-cell lymphoma
18f-fdg
measurable disease
rituximab
  • 0 views
  • 21 Mar, 2021
  • 1 location
Toripalimab Plus Rituximab Followed by R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma

Phase I portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab in treating untreated elderly diffuse large B cell lymphoma patients. The aim of phase II portion of this study will evaluate the efficacy and saftey of toripalimab plus rituximab followed by R-CHOP(rituximab, cyclophosphamide, doxorubicin, …

colony stimulating factor
b-cell lymphoma
18f-fdg
prednisone
measurable disease
  • 1 views
  • 30 Apr, 2022
  • 1 location
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

b-cell lymphoma
b-cell small lymphocytic lymphoma
chemoimmunotherapy
remission
rituximab
  • 0 views
  • 13 May, 2022
  • 1 location
Axicabtagene Ciloleucel:Neurocognitive and Patient-Reported Outcomes

The purpose of the study is to assess self-reported side effects and neurocognitive (brain, mood and thinking) functioning among patients treated with commercial axi-cel therapy.

follicular lymphoma
b-cell lymphoma
cancer
  • 0 views
  • 11 Jul, 2022
  • 1 location